文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

使用前列腺特异性膜抗原放射性配体进行前列腺癌的影像学和治疗。

Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands.

机构信息

Imaging Department, Imperial College Healthcare NHS Trust, London W6 8RF, United Kingdom.

Division of Biomedical Engineering and Imaging Sciences, Kings College London, London WC2R 2LS, United Kingdom.

出版信息

Br J Radiol. 2024 Aug 1;97(1160):1391-1404. doi: 10.1093/bjr/tqae092.

DOI:10.1093/bjr/tqae092
PMID:38733571
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11256943/
Abstract

Prostate specific membrane antigen (PSMA) directed PET imaging has rapidly transformed prostate cancer workup over the past decade and paved the way for a theranostic approach using 177Lu-labelled PSMA radioligand therapy (RLT). This review gives an overview of the underlying principles behind PSMA as a target; the current use of PSMA PET in prostate cancer imaging and benefits compared to conventional imaging; and therapeutic applications including optimisation of patient selection. It also explores the evidence base of PSMA PET for other indications not in routine clinical use and the future of PSMA-directed RLT.

摘要

前列腺特异性膜抗原（PSMA）导向的 PET 成像在过去十年中迅速改变了前列腺癌的检查方式，并为使用 177Lu 标记的 PSMA 放射性配体治疗（RLT）的治疗方法铺平了道路。本文综述了 PSMA 作为靶点的基本原理；目前 PSMA PET 在前列腺癌成像中的应用及其与传统成像相比的优势；以及治疗应用，包括优化患者选择。还探讨了 PSMA PET 在其他非常规临床应用中的适应证的证据基础，以及 PSMA 导向的 RLT 的未来。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/74e48d05ad6a/tqae092f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/c0ee579be2c0/tqae092f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/061d37ce1153/tqae092f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/354bb26b14c2/tqae092f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/8477978691f5/tqae092f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/7a4c3976a06e/tqae092f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/74e48d05ad6a/tqae092f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/c0ee579be2c0/tqae092f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/061d37ce1153/tqae092f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/354bb26b14c2/tqae092f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/8477978691f5/tqae092f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/7a4c3976a06e/tqae092f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab23/11256943/74e48d05ad6a/tqae092f6.jpg

相似文献

[1]
Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands.

Br J Radiol. 2024-8-1

[2]
Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.

Eur Urol Oncol. 2019-1-31

[3]
Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen.

Ann Nucl Med. 2020-12

[4]
Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.

Expert Rev Mol Diagn. 2016-10-14

[5]
Lu-PSMA Radioligand Therapy for Prostate Cancer.

J Nucl Med. 2017-6-29

[6]
Early treatment response assessment with [Lu]PSMA whole-body-scintigraphy compared to interim PSMA-PET.

Cancer Imaging. 2024-9-19

[7]
EANM procedure guidelines for radionuclide therapy with Lu-labelled PSMA-ligands (Lu-PSMA-RLT).

Eur J Nucl Med Mol Imaging. 2019-8-22

[8]
Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer.

Q J Nucl Med Mol Imaging. 2019-3

[9]
PSMA radioligand therapy in prostate cancer: overview, latest advances and remaining challenges.

Immunotherapy. 2019-10

[10]
Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside.

Theranostics. 2024-4-8

引用本文的文献

[1]
Prostate-Specific Membrane Antigen Expression in Colorectal Cancer and Its Potential Implication in Disease Monitoring in Rectal Cancer.

J Gastrointest Cancer. 2025-7-19

[2]
PSMA PET Imaging in the Management of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radioligand Therapy.

Target Oncol. 2025-5-26

本文引用的文献

[1]
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.

Eur Urol. 2024-8

[2]
Comparison of F-based PSMA radiotracers with [Ga]Ga-PSMA-11 in PET/CT imaging of prostate cancer-a systematic review and meta-analysis.

Prostate Cancer Prostatic Dis. 2024-12

[3]
Detection of Biochemically Recurrent Prostate Cancer with [F]DCFPyL PET/CT: An Updated Systematic Review and Meta-Analysis with a Focus on Correlations with Serum Prostate-Specific Antigen Parameters.

Tomography. 2023-8-15

[4]
Joint EANM/SNMMI procedure guideline for the use of Lu-labeled PSMA-targeted radioligand-therapy (Lu-PSMA-RLT).

Eur J Nucl Med Mol Imaging. 2023-7

[5]
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2).

Eur Urol. 2023-5

[6]
PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials.

Oncologist. 2023-5-8

[7]
Cyclotron Production of Gallium-68 Radiopharmaceuticals Using the Zn(p,n)Ga Reaction and Their Regulatory Aspects.

Pharmaceutics. 2022-12-26

[8]
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.

Eur J Nucl Med Mol Imaging. 2023-4

[9]
Cyclotron vs generator-produced 68Ga PSMA: a single-institution, prospective clinical trial.

Transl Oncol. 2023-2

[10]
Prognostic Value of Tumor Volume Assessment on PSMA PET After Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0.

J Nucl Med. 2023-4

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索